Tempus expands multi-year collaboration with Moderna, Merck on V940 melanoma vaccine commercialization support

PUBT · 2d ago
Tempus expands multi-year collaboration with Moderna, Merck on V940 melanoma vaccine commercialization support
  • Tempus expanded a multi-year collaboration with Moderna, Merck to support potential commercialization of personalized cancer vaccine intismeran autogene (V940/mRNA-4157).
  • Scope covers sample collection logistics for tumor tissue and blood required for next-generation sequencing, a key step in individualized therapy workflows.
  • Tempus is set to provide sequencing services, subject to regulatory approvals, to support therapy design and manufacturing.
  • Program targets patients with completely resected stage IIB-IV melanoma, with evaluation in other cancer types.
  • Financial terms were not disclosed.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tempus AI Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261007586639) on October 07, 2026, and is solely responsible for the information contained therein.